Emibetuzumab
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type) . Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].
Product Specifications
CAS Number
[1365287-97-3]
Product Name Alternative
LY2875358
UNSPSC
12352203
Target
C-Met/HGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/emibetuzumab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Emibetuzumab]
Molecular Weight
(144.56 kDa)
References & Citations
[1]Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20 (23) :6059-70.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
136255 50 µL
Mknk1 (Mknk1, Mnk1, MAP kinase-interacting serine/threonine-protein kinase 1, MAP kinase signal-interacting kinase 1) discontinued
Ask
View Details 